Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Huang, Yen-HsiangYen-HsiangHuangTseng, Jeng-SenJeng-SenTsengHsu, Kuo-HsuanKuo-HsuanHsuChen, Kun-ChiehKun-ChiehChenKANG-YI SUSUNG-LIANG YUChen, Jeremy J WJeremy J WChenYang, Tsung-YingTsung-YingYangChang, Gee-ChenGee-ChenChang2021-11-102021-11-102021-08-302045-2322https://scholars.lib.ntu.edu.tw/handle/123456789/586614The original version of this Article contained errors in Table 4, where the P value was omitted and the “Adjusted HR (95% CI)a” value for “ECOG PS” was incorrectly assigned. The correct and incorrect values appear below. Incorrect: (Table presented.). The original Article has been corrected.enPublisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790Merratum10.1038/s41598-021-97248-w344625212-s2.0-85114244950https://scholars.lib.ntu.edu.tw/handle/123456789/582775